Effect of semaglutide 2.4 mg once weekly on 10‐year type 2 diabetes risk in adults with overweight or obesity
Authors' conclusion
Cardiometabolic Disease Staging risk assessment suggests that once-weekly semaglutide 2.4 mg may substantially lower 10-year T2D risk in people with overweight or obesity.
Study context
- Population
- Adults with obesity (or overweight with weight-related comorbidities) in STEP 1 (68 weeks), STEP 4 and STEP 5 (104 weeks)STEP 1
- Participants
- 1,583 adults
- Comparison
- Semaglutide 2.4 mg once weekly vs placebo
- Primary endpoint
- Relative change in 10-year T2D risk score (Cardiometabolic Disease Staging)
Methodological detailsplacebo-controlled
- Placebo-controlled
Primary result
As reported in the abstract
Relative 10-year T2D risk score change, STEP 1 · 68 weeks
Semaglutide
−61.1%
Placebo
−12.9%
P < 0.0001
Further findings
10-year T2D risk score, STEP 4 (N = 776) · week 68 · placebo = withdrawal
P < 0.0001
Relative risk score change Semaglutide −32.1% · Placebo +40.6%
| Outcome | Semaglutide | Placebo | P value |
|---|---|---|---|
| Relative 10-year T2D risk score change, STEP 5 (N = 295) · week 104 | −60.0% | 3.5% | P < 0.0001 |
10-year T2D risk score, STEP 4 (N = 776) · week 68
- Risk score during run-in reduced from 20.6% to 11.1%
- Risk score reductions mirrored weight loss
Original publication
Effect of semaglutide 2.4 mg once weekly on 10‐year type 2 diabetes risk in adults with overweight or obesity. Obesity (Silver Spring). Published 22 August 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →